Hospital
Christus Health Central Louisiana
Christus Health Central Louisiana was paid $4.88M by Medicaid between Jan 2018 and Dec 2024, across 78 billing codes. Its largest line is 99283, emergency room visit (moderate) — 42% of everything it billed.
33Billing provider infoCHRISTUS HEALTH CENTRAL LOUISIANA
COUSHATTA, LA 71019
COUSHATTA, LA 71019
33aNPI1205824208assigned 10/12/2005
33bProvider typeCritical Access Hospital
28Total paid$4.88M
24GClaims92,509
24DCodes billed78
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Critical Access Hospital providers in Louisiana
Rank by total paid#15 of 40
Median peer was paid$3.19M
This provider vs. median1.5×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official WILSON, MONTE controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 15,452 | $774K | |
| 2019 | 14,919 | $594K | |
| 2020 | 8,155 | $292K | |
| 2021 | 11,903 | $523K | |
| 2022 | 14,189 | $899K | |
| 2023 | 16,142 | $1.02M | |
| 2024incomplete | 11,749 | $785K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 42% | 8,394 | 7,567 | $2.05M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 26% | 3,097 | 2,781 | $1.25M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 8.3% | 1,242 | 1,027 | $406K |
| G0378 | Hospital observation service, per hour | 4.3% | 418 | 268 | $210K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.1% | 602 | 563 | $104K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.8% | 1,447 | 1,122 | $86K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.5% | 13,048 | 9,560 | $74K |
| 80050 | General health panel | 1.4% | 1,691 | 1,595 | $70K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.4% | 919 | 811 | $67K |
| 80053 | Comprehensive metabolic panel | 1.2% | 7,832 | 6,532 | $60K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 1.2% | 1,439 | 1,345 | $57K |
| 36415 | Collection of venous blood by venipuncture | 1.2% | 25,492 | 18,816 | $56K |
66 more codes
| 71045 | Radiologic examination, chest; single view | <1% | 918 | $46K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 530 | $44K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 554 | $39K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 30 | $27K |
| 0240U | <1% | 277 | $26K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 1,398 | $22K |
| 80061 | Lipid panel | <1% | 1,630 | $19K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 3,816 | $16K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,238 | $14K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 37 | $13K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 567 | $12K |
| 83735 | <1% | 2,339 | $11K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,708 | $11K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 260 | $9K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,069 | $8K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 256 | $6K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 34 | $6K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 776 | $5K |
| 80069 | <1% | 860 | $5K | |
| 84484 | <1% | 784 | $5K | |
| 81003 | <1% | 2,799 | $4K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 33 | $4K |
| 0012A | <1% | 154 | $4K | |
| 84439 | <1% | 468 | $3K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 58 | $3K |
| 81002 | <1% | 1,046 | $3K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 113 | $3K |
| 0011A | <1% | 196 | $2K | |
| G0379 | Direct admission of patient for hospital observation care | <1% | 21 | $2K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 45 | $2K |
| 86328 | <1% | 63 | $2K | |
| 84100 | <1% | 450 | $2K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 121 | $1K |
| 84481 | <1% | 128 | $1K | |
| 82553 | <1% | 216 | $1K | |
| 0064A | <1% | 96 | $1K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 66 | $1K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 158 | $965.17 |
| 82550 | <1% | 237 | $773.07 | |
| 0001A | <1% | 27 | $645.50 | |
| 82607 | <1% | 51 | $625.36 | |
| 81025 | <1% | 120 | $620.91 | |
| 83880 | <1% | 82 | $550.03 | |
| 80074 | <1% | 15 | $519.29 | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 16 | $484.88 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 102 | $419.86 |
| 80305 | <1% | 44 | $418.84 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 20 | $406.72 |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 13 | $350.90 |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 13 | $350.90 |
| 82728 | <1% | 13 | $177.87 | |
| 84466 | <1% | 13 | $166.52 | |
| 83540 | <1% | 25 | $149.13 | |
| 83690 | <1% | 26 | $146.09 | |
| 85610 | <1% | 44 | $107.94 | |
| 85730 | <1% | 27 | $102.65 | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 59 | $72.06 |
| 91301 | <1% | 275 | $5.51 | |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | <1% | 14 | $5.05 |
| T1015 | A visit at a community health center or clinic (one all-in rate) | 0% | 64 | $0.00 |
| 91300 | 0% | 80 | $0.00 | |
| 00000 | 0% | 30 | $0.00 | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 0% | 21 | $0.00 |
| 96375 | Therapeutic injection; each additional sequential IV push | 0% | 96 | $0.00 |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 0% | 35 | $0.00 |
| 91306 | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialWILSON, MONTE (CEO)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.